Search results for:
nirsevimab (RSV monoclonal antibody - peds/neo)
nirsevimab (RSV monoclonal antibody - peds/neo)
| Drug Name |
Form |
Strength |
Notes |
| Beyfortus |
SOLUTION, INTRAMUSCULAR |
preservative-free 100 mg/mL (1 mL and 0.5 mL prefilled syringes) |
|
Last updated: Jan. 29, 2026
Outpatient: Formulary (as recommended by ACIP)
Inpatient: Formulary, Restricted to infants born in RSV season and whose mother did not receive the RSV vaccine > 14 days prior to delivery and meeting 1 of the following:
Please provide caregivers of eligible neonates with the Immunization Information Statement. (link: Immunization Information Sheet-RSV Preventive Antibody: What You Need to Know-September 25, 2023 (cdc.gov))